intravitreal injection with ranibizumab — Competitive Intelligence Brief

intravitreal injection with ranibizumab (intravitreal injection with ranibizumab) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor (monoclonal antibody fragment). Area: Ophthalmology.

marketed VEGF inhibitor (monoclonal antibody fragment) VEGF-A (Vascular Endothelial Growth Factor A) Ophthalmology Small molecule

Target snapshot

intravitreal injection with ranibizumab (intravitreal injection with ranibizumab) — University Hospital Muenster. Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
intravitreal injection with ranibizumab TARGET	intravitreal injection with ranibizumab	University Hospital Muenster	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Lucentis (Treat and extend)	Lucentis (Treat and extend)	Retinal Consultants of Arizona	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A
intravitreal ranibizumab injections	intravitreal ranibizumab injections	Hospital Regional de São José - Dr. Homero de Miranda Gomes	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Ranibizumab and laser	Ranibizumab and laser	Fukushima Medical University	marketed	VEGF inhibitor (monoclonal antibody fragment) combined with laser photocoagulation	VEGF-A
Ranibizumab injection and TTT - ICG based	Ranibizumab injection and TTT - ICG based	New England Retina Associates	phase 3	VEGF inhibitor (monoclonal antibody fragment) combined with thermal ablation guidance	VEGF-A
Ranibizumab + laser	Ranibizumab + laser	Jaeb Center for Health Research	phase 3	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor (monoclonal antibody fragment) class)

1. Hospital Regional de São José - Dr. Homero de Miranda Gomes · 1 drug in this class
2. Jaeb Center for Health Research · 1 drug in this class
3. Retinal Consultants of Arizona · 1 drug in this class
4. University Hospital Muenster · 1 drug in this class